

- A**
- Aberrant DNA methylation, 461
 - Absolute lymphocyte count, 380, 477
 - ABVD therapy, 528, 586
 - Adjuvant therapy, 251
 - Adolescents, 77, 78, 80, 170, 172, 532, 578
 - Adult T-cell leukemia, 516
 - Aggressive lymphoma, 9, 49, 53, 89, 93, 120, 192, 214, 261, 262, 268, 290, 322, 393, 397, 418, 432, 452, 460, 575, 588
 - AIDS, 27, 168, 226
 - Alemtuzumab, 111, 376, 378, 383
 - Alkylating agents, 8, 110, 132, 140, 163, 170, 375, 379, 503
 - Allogeneic bone marrow transplantation, 504, 577
 - Allogeneic hematopoietic stem cell transplantation, 3
 - Allogeneic stem cell transplantation, 30, 244, 384, 558
 - Allogeneic transplantation, 168
 - Allogenic transplantation, 528
 - All-trans-retinoic acid (ATRA), 452
 - Anaplastic large cell lymphoma, 19, 30, 80, 81, 95, 108, 122, 173, 176, 235, 241, 262
 - Anaplastic lymphoma kinase, 80, 509, 577
 - Anemia, 15, 17, 19, 114, 164, 180, 206, 227, 244, 257, 264, 295, 312, 335, 362, 363, 424, 429, 434, 446, 500, 503, 510, 516, 536, 565, 574
 - Angiogenesis, 191, 197, 200, 451
 - Angiogenic factors, 398
 - Angioimmunoblastic T-cell lymphoma, 96, 114, 122, 234
 - Animal models, 6, 41, 46, 98, 106, 245, 247, 248, 251, 252, 253, 258, 276, 283, 287, 291, 293, 298, 332, 357, 394, 401, 513, 529, 546, 558, 562
 - Anthracyclines, 3, 43, 113, 114, 126, 175, 210, 212, 316, 328, 336, 339, 340, 362, 363, 366, 401, 423, 428, 454, 456, 461, 566, 571, 575
 - Antiangiogenic therapy, 290, 451
 - Antibody response, 140
 - Anti-CD20 antibody, 18, 28, 495
 - Anti-CD20 monoclonal antibody, 495, 561
 - Anti-CD30 antibody, 142
 - Antiretroviral therapy, 27
 - Anti-tumor immunity, 253
 - Anxiety, 310
 - Apoptosis, 17, 21, 26, 37, 38, 45, 55, 99, 106, 111, 115, 132, 141, 144, 152, 154, 155, 157, 188, 195, 258, 260, 276, 282, 283, 287, 293, 298, 308, 353, 371, 373, 381, 390, 391, 392, 399, 402, 403, 415, 435, 449, 522, 530, 531, 562
 - ASCT, 14, 28, 44, 54, 66, 95, 110, 119, 125, 161, 165, 210, 210, 216, 217, 218, 219, 222, 233, 238, 240, 303, 305, 326, 336, 337, 338, 340, 341, 345, 354, 383, 403, 442, 454, 464, 466, 476, 506, 525, 526, 531, 541, 542, 544, 549, 563, 575, 579, 584
 - Asthenia, 427
 - Autoantibodies, 595
 - Autologous bone marrow transplantation, 469, 554
 - Autologous hematopoietic stem cell transplantation, 543
 - Autologous peripheral blood stem cell transplantation, 512, 554
 - Autologous stem cell support, 18, 220, 354, 528
 - Autologous stem cell transplantation, 28, 119, 167, 210, 218, 222, 238, 240, 304, 305, 326, 337, 338, 341, 428, 454, 453, 464, 476, 514, 542, 544, 548, 549, 553, 557, 563, 575, 579
 - Autologous transplantation, 1, 13, 18, 28, 66, 119, 140, 141, 142, 167, 210, 217, 218, 219, 220, 221, 222, 238, 240, 243, 244, 249, 251, 265, 286, 295, 304, 305, 326, 337, 338, 340, 341, 345, 354, 362, 411, 428, 437, 454, 453, 464, 469, 472, 475, 476, 506, 512, 513, 514, 525, 535, 540, 541, 542, 544, 548, 549, 551, 553, 557, 563, 575, 579
 - Autopsy, 3, 140, 537
- B**
- B symptoms, 39, 54, 68, 77, 91, 125, 168, 170, 180, 201, 219, 232, 313, 323, 361, 363, 365, 379, 383, 405, 425, 433, 480, 498, 507, 509, 510, 511, 515, 519, 520, 521, 564, 596
 - B-ALL, 8, 82, 83, 393
 - Basic fibroblast growth factor, 398
 - Bax, 26, 391, 452
 - B-cell chronic lymphocytic leukemia, 372
 - B-cell differentiation, 185
 - B-cell lymphoma, 1, 7, 46, 47, 53, 69, 93, 94, 108, 109, 122, 127, 130, 134, 139, 232, 252, 272, 287, 299, 305, 334, 344, 359, 365, 393, 490, 491, 510, 514, 571
 - B-cell lymphoproliferative disorders, 298
 - B-cell malignancies, 145
 - B-cell type, 283, 496
 - Bcl-2, 26, 51, 54bis, 70, 71, 101, 111, 129, 154, 188, 189, 282, 283, 319, 324, 333, 366, 391, 395, 457, 462, 476, 496, 543
 - BCL-2 expression, 45, 233
 - BCL-2 gene, 202
 - BCL-6, 43, 51, 201, 458
 - B-CLL, 67, 341, 369, 370, 371, 372, 378, 408, 440, 558
 - Bcl-X, 102
 - Bcl-xl, 102
 - BCNU, 66, 181, 340, 554
 - BEACOPP regimen, 116, 160, 161, 162, 519, 523, 524, 527, 528, 534, 564, 571, 586
 - BEAM regimen, 210, 212
 - Bendamustine, 132, 295, 302, 379, 428, 432
 - Bexxar, 15, 332, 422
 - bFGF, 290, 398
 - Binet stage A, 22, 370, 415
 - Bleomycin, 158, 166, 201, 227, 532
 - Blood–brain barrier, 487
 - Bone disease, 590
 - Bone marrow, 16, 19, 27, 58, 79, 106, 108, 111, 132, 159, 172, 173, 176, 180, 200, 201, 233, 248, 252, 254, 269, 270, 273, 283, 293, 299, 304, 318, 323, 324, 326, 331, 332, 333, 334, 363, 367, 378, 383, 404, 405, 409, 412, 422, 425, 433, 436, 437, 440, 454, 458, 475, 478, 482, 484, 493, 494, 500, 515, 521, 543, 556, 557, 563, 573, 574, 575, 576, 584, 591, 595
 - Bone marrow, biopsy, 159, 422, 478, 485
 - Bone marrow, involvement, 16, 27, 58, 79, 159, 173, 180, 233, 304, 323, 331, 332, 454, 475, 494, 515, 543, 573, 578
 - Bone marrow, transplantation, 487
 - Brain natriuretic peptide, 573
 - Breast cancer, 77, 386
 - Breast involvement, 499
 - Burkitt's lymphoma, 8, 146, 193, 224, 275, 496
 - Burkitt-like lymphoma, 282, 496
- C**
- Campath-1H, 377
 - CAMPATH-1H, 376, 403
 - Carboplatin, 83, 345, 554
 - Cardiac toxicity, 226, 536, 573
 - Case–control study, 97, 225, 275
 - Caspase 3, 452
 - 2CdA, 539
 - CD10 expression, 319, 499
 - CD15, 152, 409, 523
 - CD20, 1, 13, 43, 53, 76, 84, 85, 98, 100, 111, 132, 143, 144, 152, 156, 181, 201, 206, 212, 218, 269, 270, 277, 299, 306, 325, 331, 336, 344, 355, 363, 369, 372, 398, 405, 409, 412, 419, 420, 422, 423, 425, 428, 429, 436, 447, 455, 471, 473, 486, 498, 502, 566, 567, 568, 569, 577
 - CD20 antigen, 76, 306, 505
 - CD20 expression, 76, 100, 428
 - CD20 protein, 77
 - CD20⁺, 13, 43, 53, 76, 84, 181, 206, 212, 270, 277, 299, 325, 331, 344, 363, 369, 409, 412, 419, 423, 428, 429, 447, 498, 570
 - CD23, 22, 67, 87, 111, 131, 145, 256, 296, 297, 369, 414, 415, 443
 - CD3, 76, 108, 249, 401, 412, 504, 511, 555
 - CD30, 115, 141, 152, 173, 176, 409, 511, 520, 529, 577
 - CD30 expression, 141, 532
 - CD34+ cells, 27, 345, 525, 541, 543, 544, 545, 547, 548, 552
 - CD35– cells, 201
 - CD38, 22, 25, 49, 111, 251, 269, 277, 296, 297, 359, 369, 370, 372, 373, 375, 414, 545, 577
 - CD38 expression, 22, 111, 370, 373, 375, 417
 - CD40, 24, 48, 99, 132, 132, 190, 248, 273, 399, 405
 - CD5 expression, 67, 363
 - CD5⁺, 67, 76, 111, 256, 296, 299, 304, 369, 371, 390bis, 409, 412, 414, 415, 443
 - CD80, 132, 143, 249
 - Cell cultures, 358
 - Cell cycle, 26, 42, 55, 72, 141, 157, 195, 265, 283, 293, 298, 308, 360, 381, 392, 531, 562
 - Cell development, 106
 - Cell lines, 6, 7, 10, 33, 37, 42, 45, 46, 47, 48, 49, 50, 69, 101, 105, 115, 136, 144, 152, 154, 155, 157, 191, 193, 195, 245, 248, 251, 258, 260, 275, 278, 287, 290, 293, 298, 299, 308, 390, 391, 393, 399, 435, 449, 458, 488, 511, 530, 559, 577
 - Central nervous system, 9, 18, 39, 40, 54, 62, 63, 64, 65, 66, 79, 85, 109, 174, 186, 206, 224, 254, 282, 299, 349, 351, 352, 362, 363, 438, 457, 475, 483, 484, 485, 486, 487, 488, 489, 493, 495, 496, 497, 535, 553, 579
 - Central nervous system, lymphoma, 490
 - CGH, 36, 152, 184, 185, 234, 267, 279, 322, 360, 400, 438
 - Chemoimmunotherapy, 312, 393, 423, 431, 452, 469
 - Chemokine, 24, 37, 137, 155, 200, 230, 235, 255, 346, 380, 483, 488, 523
 - Chemokine, receptors, 235, 483, 488, 523
 - Chemoradiotherapy, 125, 229, 365, 508, 514, 544, 564
 - Chemoresistance, 267, 293, 298, 374, 577
 - Chemosensitivity, 204, 530, 584
 - Chemotherapy, 1, 3, 4, 5, 8, 9, 12, 13, 14, 15, 16, 18, 27, 28, 29, 39, 40, 52, 53, 54bis, 62, 66, 76, 77, 78, 79, 81, 82, 83, 84, 85, 90, 91, 100, 109, 113, 116, 117, 120, 124, 125, 126, 129, 132, 134, 140, 143, 146, 160, 161, 162, 163, 165, 166, 167, 168, 170, 172, 173, 177, 180, 184, 188, 198, 202, 205, 208, 212, 213, 214, 215, 216, 217, 218, 221, 222, 223, 224, 226, 229, 235, 237, 249, 252, 253, 257, 265, 287, 289, 294, 295, 300, 303, 305, 310, 313, 316, 317, 323, 329, 330, 333, 335, 337, 339, 342, 344, 345, 355, 356, 359, 362, 363, 364, 365, 374, 379, 386, 388, 391, 393, 402, 403, 406, 416, 417, 420, 425, 429, 433, 437, 438, 441, 443, 453, 454, 452, 453, 455, 456, 457, 460, 462, 463, 465, 467, 468, 469, 470, 471, 472, 473, 477, 481, 483, 484, 486, 489, 490, 493, 495, 497, 498, 500, 502, 505, 506, 508, 509, 510, 511, 512, 514, 515, 516, 522, 523, 524, 526, 529, 531, 534, 535, 538, 541, 542, 543, 544, 547, 548, 549, 551, 553, 554, 558, 559, 561,

- 563, 567, 569, 570, 571, 575, 576, 577, 578, 583, 586, 591
- Childhood lymphoma, 174
- Chlorambucil, 329, 379, 412, 481, 494, 498, 507
- CHOP regimen, 1, 13, 28, 34, 39, 44, 51, 52, 53, 54, 54bis, 63, 74, 76, 77, 84, 93, 94, 96, 121, 126, 134, 135, 146, 182, 183, 184, 185, 186, 189, 192, 196, 198, 199, 201, 203, 204, 205, 206, 207, 210, 210, 210, 212, 213, 214, 215, 221, 222, 228, 233, 257, 269, 279, 289, 290, 300, 301, 302, 303, 304, 317, 326, 330, 338, 341, 349, 354, 355, 363, 364, 365, 393, 403, 405, 412, 413, 425, 426, 431, 433, 438, 441, 445, 447, 452, 455, 457, 460, 463, 466, 470, 471, 473, 474, 475, 477, 480, 482, 497, 498, 508, 509, 510, 512, 514, 515, 516, 543, 550, 551, 569, 570, 571, 576
- CHOP resistance, 280
- CHOP therapy, 183, 203, 210, 233, 317, 546
- Chromosomal aberrations, 7, 268, 372, 410
- Chromosomal abnormalities, 67, 413
- Chromosomal translocation, 80, 278, 284, 285, 286, 392
- Chronic lymphocytic leukemia, 19, 107, 132, 256, 274, 278, 334, 408, 411, 412, 414, 418
- Cisplatin, 224, 467, 468, 526, 547, 552
- Cladribine, 335, 419
- Clinical trials, 15, 17, 31, 46, 54bis, 74, 79, 93, 98, 118, 121, 132, 134, 136, 139, 144, 165, 212, 222, 247, 252, 253, 256, 293, 308, 311, 341, 377, 403, 424, 454, 453, 466, 512, 513, 519, 544, 565
- Clinical trials, design, 4
- Clinical outcome, 25, 51, 56, 57, 120, 139, 186, 202, 212, 219, 231, 240, 246, 256, 269, 290, 314, 317, 319, 326, 339, 351, 355, 359, 364, 370, 373, 383, 385, 414, 465
- Clinical presentations, 349
- Clinical stage, 111, 172, 229, 346, 377, 388, 442, 486, 510, 515, 516, 534, 564, 598
- Clinicopathological, features, 272, 503, 512
- Clonal evolution, 201, 373, 402
- Colony-stimulating factor, 554
- Combination chemotherapy, 3, 47, 163, 201, 334, 377, 426, 428, 492
- Combination treatment, 1, 3, 8, 23, 44, 47, 53, 54bis, 56, 83, 89, 93, 96, 98, 103, 105, 110, 112, 114, 120, 132, 134, 143, 145, 154, 163, 170, 182, 186, 201, 226, 227, 237, 244, 253, 254, 256, 257, 258, 260, 264, 267, 279, 286, 293, 295, 298, 301, 302, 315, 317, 318, 334, 352, 353, 377, 378, 381, 403, 404, 413, 414, 415, 426, 427, 428, 429, 441, 444, 448, 479, 481, 489, 494, 505, 528, 529, 530, 531, 536, 537, 552, 553, 558, 560, 580
- Combined immuno-chemotherapy, 300, 331
- Combined modality therapy, 117, 529, 561, 580
- Combined modality treatment, 453
- Combined therapy, 90, 546, 563
- Complete response, 5, 12, 18, 20, 40, 77, 83, 100, 113, 137, 144, 145, 185, 201, 202, 203, 216, 217, 221, 233, 237, 244, 257, 259, 261, 307, 329, 355, 356, 364, 405, 406, 416, 428, 441, 446, 453, 455, 456, 460, 467, 474, 490, 497, 498, 505, 510, 516, 523, 547, 550, 557, 565, 578
- Computed tomography, 5, 15, 20, 27, 43, 78, 90, 116, 120, 121, 122, 125, 126, 136, 137, 159, 160, 167, 172, 202, 203, 204, 212, 222, 226, 227, 237, 289, 305, 312, 325, 342, 358, 363, 388, 403, 412, 419, 420, 422, 425, 431, 432, 440, 454, 452, 465, 478, 482, 486, 502, 505, 510, 515, 516, 528, 531, 535, 541, 548, 549, 560, 578, 582, 583, 585, 586, 587, 591
- Concurrent therapy, 26, 72, 201, 229, 439
- Conventional chemotherapy, 238, 243, 300, 307, 341, 471, 473, 476, 512
- Conventional cytogenetic analysis, 293
- COP regimen, 572
- Cutaneous involvement, 502
- Cutaneous T-cell lymphoma, 134, 241, 242, 261, 515
- Cyclin, D1, 26, 293, 298, 299, 308, 440, 498, 562
- Cyclin-dependent kinase, 132, 392, 452
- Cyclophosphamide, 40, 60, 79, 110, 145, 162, 165, 171, 173, 183, 194, 201, 220, 226, 227, 256, 300, 334, 335, 336, 337, 338, 340, 371, 377, 378, 414, 415, 444, 446, 448, 460, 461, 512, 537, 541, 545, 566
- Cytarabine, 40, 66, 77, 173, 300, 301, 304, 305, 336, 339, 352, 438, 441, 444, 468, 487, 489, 544, 549, 551, 553, 566
- Cytogenetic, 61, 68, 111, 127, 152, 179, 193, 198, 285, 297, 310, 360, 373, 382, 408, 410, 436, 585
- Cytogenetic, abnormalities, 111, 413
- Cytogenetic, aberrations, 61, 297, 360, 383
- Cytogenetic, normalities, 111, 413
- Cytogenetic, analysis, 436, 585
- Cytogenetic, features, 69
- Cytogenetic, abnormalities, 111, 413
- Cytokines, 42, 155, 167, 192, 230, 255, 286, 380, 545
- Cytomorphology, 65
- Cytoreduction, 250, 304
- Cytotoxic T-cells (CTL), 37
- Cytotoxic therapy, 14
- Cytotoxic, chemotherapy, 85
- Cytotoxicity, 154, 251, 260, 398, 411, 463, 513, 561
- D**
- Dacarbazine, 166, 532
- Death, 8, 42, 45, 46, 58, 63, 65, 98, 106, 118, 119, 136, 152, 154, 155, 162, 163, 165, 171, 206, 210, 210, 220, 228, 239, 244, 258, 260, 264, 265, 272, 276, 286, 289, 298, 302, 312, 353, 364, 389, 390, 402, 434, 449, 452, 461, 482, 487, 492, 522, 530, 534, 544, 551, 563, 597
- Dendritic cells, 2, 70, 87, 108, 139, 142, 143, 156, 248, 267, 443
- Depression, 309, 470
- Developing countries, 181
- Dexamethasone, 110, 243, 293, 333, 445, 467, 468, 489, 550
- DHAP regimen, 413, 471
- Differentiation, 46, 70, 105, 106, 107, 190, 196, 197, 240, 269, 283, 347, 477, 595
- Diffuse aggressive lymphoma, 90
- Diffuse large B-cell lymphoma, 1, 3, 7, 39, 41, 42, 45, 46, 47, 48, 74, 83, 85, 97, 108, 109, 123, 149, 150, 172, 183, 186, 187, 188, 190, 191, 193, 194, 198, 201, 204, 208, 210, 216, 221, 263, 266, 282, 283, 284, 285, 319, 332, 347, 350, 353, 355, 358, 362, 363, 364, 399, 455, 457, 459, 463, 464, 472, 480, 486, 493, 497, 569, 575, 580, 584, 595
- Diffuse large cell lymphoma, 40, 89, 411
- Disease progression, 18, 19, 38, 58, 118, 128, 165, 202, 221, 237, 238, 255, 293, 301, 302, 307, 321, 332, 356, 413, 484, 555, 557, 572
- DNA, 10, 33, 38, 41, 46, 55, 61, 69, 74, 75, 86, 100, 122, 148, 179, 184, 185, 193, 194, 196, 229, 231, 234, 244, 267, 275, 278, 289, 293, 298, 318, 320, 322, 348, 357, 366, 374, 382, 390bis, 392, 406, 408, 458, 503, 559, 592, 596
- DNA, methylation, 33, 55, 394
- Dose dense chemotherapy, 473
- Dose escalation, 19, 46, 99, 101, 141, 162, 244, 254, 307
- Dose intensification, 528
- Dose intensity, 224
- Doxorubicin, 40, 162, 164, 166, 173, 183, 201, 212, 213, 226, 305, 336, 337, 401, 444, 461, 529, 573
- Drug resistance, 24, 293, 298, 393, 446
- Durable remission, 3, 29, 180, 305, 515
- E**
- EBV-DNA, 229, 276
- Elderly, 1, 52, 53, 54, 93, 94, 110, 112, 149, 158, 166, 182, 212, 213, 214, 215, 222, 300, 303, 304, 333, 352, 362, 429, 442, 454, 460, 461, 465, 470, 495, 501, 502, 512, 515, 553
- Elderly patients, 1, 52, 54, 110, 158, 166, 182, 212, 213, 215, 300, 304, 362, 429, 460, 501, 502, 512, 553
- Endostatin, 291
- Enteropathy-associated T-cell lymphoma, 124
- Epirubicin, 212, 228
- EPOCH, 9, 43, 121, 206, 474
- Epratuzumab, 20, 132, 144, 258
- ESHAP, 210, 216, 403, 464, 515, 552
- Etoposide, 40, 79, 83, 94, 158, 162, 165, 173, 201, 226, 336, 339, 340, 345, 448, 461, 467, 469, 541, 545, 547, 551, 556
- Event-free survival, 31, 53, 90, 92, 175, 180, 191, 195, 202, 210, 217, 219, 302, 323, 345, 355, 429, 456, 550, 575, 596
- Expression profiles, 72, 115, 187, 230, 284, 525
- Extended survival, 453, 485
- Extranodal involvement, 39, 53, 94, 168, 282, 341, 349, 350, 366, 396, 405, 439, 474, 499, 524
- Extranodal lymphoma, 41, 123, 355, 478, 488, 497, 501
- F**
- Family history, 149
- Fas, 37, 276, 287, 380, 404
- Fas-mediated apoptosis, 276, 288
- FCR, 145, 256, 414, 415, 540
- Fertility, 160, 565
- Field radiotherapy, 44, 117, 181
- Fine needle aspiration biopsy, 591
- First relapse, 165, 218, 336, 338, 485, 530
- First remission, 14, 28, 177, 331, 341, 421, 517
- First-line therapy, 229, 302, 355, 420, 436
- FISH, 36, 38, 48, 60, 61, 67, 70, 74, 128, 152, 185, 186, 193, 194, 198, 275, 278, 285, 290, 296, 297, 299, 310, 360, 366, 372, 373, 374, 378, 382, 390bis, 400, 436, 577
- FISH analysis, 48, 152, 278, 285, 297
- Flavopiridol, 382
- Flow cytometry, 22, 42, 76, 109, 145, 154, 256, 283, 286, 296, 304, 369, 377, 378, 380, 414, 415, 440, 449, 546, 555
- Fludarabine, 16, 26, 60, 111, 145, 181, 220, 256, 333, 336, 345, 371, 375, 376, 377, 378, 379, 381, 382, 414, 415, 423, 425, 427, 438, 446, 537, 565, 566, 576
- Follicular dendritic cells, 131, 281, 322
- Follicular lymphoma, 2, 3, 12, 15, 16, 20, 24, 56, 58, 68, 70, 86, 87, 97, 101, 107, 112, 123, 130, 139, 149, 191, 198, 210, 254, 263, 269, 277, 282, 283, 286, 310, 311, 312, 315, 319, 320, 322, 323, 324, 326, 327, 328, 329, 330, 332, 334, 337, 338, 341, 342, 350, 395, 404, 418, 419, 421, 422, 430, 432, 433, 434, 436, 458, 468, 470, 492, 502, 555, 569, 580, 592
- Follicular lymphoma, advanced stage, 28, 330, 342
- G**
- Gastric MALT lymphoma, 313, 346, 361, 497
- Gastrointestinal tract, 311
- G-CSF, 15, 54, 83, 96, 164, 206, 217, 303, 377, 424, 443, 446, 461, 470, 526, 543, 545, 549, 551, 557
- Gemcitabine, 134, 166, 401, 403, 526, 532
- Gene alterations, 74, 284
- Gene amplification, 494
- Gene expression, 3, 6, 10, 24, 34, 35, 50, 55, 73, 88, 102, 105, 107, 108, 115, 127, 155, 184, 186, 190, 191, 195, 196, 234, 280, 291, 297, 299, 317, 322, 348, 351, 373, 381, 399, 438
- Gene expression profiling, 6, 10, 34, 50, 73, 102, 127, 184, 186, 191, 196, 234, 297, 299, 317, 348, 352
- Gene rearrangements, 70, 82, 186, 198, 285, 413, 458, 491, 507
- Genetic polymorphism, 148, 233
- Genetic analysis, 349
- Genetic polymorphisms, 148, 233
- Genomic aberrations, 234, 268, 361
- Genomic profiling, 278, 361
- Germinal center, 34, 46, 50, 68, 74, 104, 107, 115, 184, 188, 196, 201, 281, 283, 405, 455, 462
- GM-CSF, 57, 139, 247, 248, 250, 286, 554

Graft-versus-host disease, 31, 32
 Graft-versus-leukemia effect, 414
 Graft-versus-lymphoma effect, 3
 Growth factors, 396, 468, 549, 560

H

Hairy cell leukemia, 419
 HD9 trial, 163
 Healthcare, 123
 Heat shock proteins, 533
Helicobacter pylori, 346, 357, 360
 Hematological malignancies, 176, 380
 Hematological recovery, 557
 Hematological toxicity, 65, 167, 177, 300, 303, 446, 468, 545, 565, 576
 Hematopoiesis, 106, 267
 Hemoglobin, 58, 168, 319, 323, 350, 470, 521, 565, 571, 575
 Hemophagocytic syndrome, 382, 511
 Hepatic toxicity, 165, 423
 Hepatitis C, 225, 494
 Hepatitis C virus, 494
 Hepatocellular carcinoma, 463
 Heterozygosity, 2, 61, 179, 193, 196, 267, 284, 438
 High grade B-cell lymphoma, 496
 High risk patients, 3, 38, 188, 204, 210, 453, 553
 High tumor burden, 336, 340, 492, 532
 High-dose chemotherapy, 118, 160, 221, 238, 240, 304, 305, 337, 345, 362, 428, 468, 472, 535, 547, 552, 553, 559, 563, 580
 High-dose cyclophosphamide, 306
 High-dose cytarabine, 300, 547
 High-dose methotrexate, 66, 210, 301, 438, 498
 High-dose therapy, 1, 4, 13, 29, 83, 220, 243, 332, 337, 354, 383, 445, 468, 542, 544, 550, 566
 Histiocytosis, 388
 Histological subtypes, 15, 30, 283, 341, 471
 Histological transformation, 72, 130, 135, 310, 322, 340
 Histone deacetylase inhibitor, 134, 259, 382
 HIV infection, 169
 HIV-associated lymphoma, 460
 HLA antigens, 30, 31, 32, 54bis, 152, 220, 245, 384, 595
 Hodgkin's disease, 120, 152, 163, 180, 548, 551, 563
 Hodgkin's lymphoma, 4, 5, 16, 19, 27, 29, 31, 43, 78, 91, 108, 112, 115, 116, 117, 118, 119, 120, 121, 124, 125, 129, 136, 137, 141, 147, 151, 152, 154, 155, 156, 157, 158, 159, 161, 162, 164, 165, 166, 167, 170, 200, 217, 260, 262, 265, 289, 365, 386, 387, 396, 406, 432, 469, 481, 518, 519, 521, 522, 523, 524, 525, 527, 528, 529, 530, 531, 532, 533, 534, 535, 542, 551, 553, 555, 561, 563, 564, 572, 578, 579, 580, 586, 593, 594, 598
 Hypercalcemia, 141, 306, 519
 Hypoproteinemia, 574
 Hypoxia, 200, 365

I

Idarubicin, 461, 492
 Idiotype vaccine, 139, 223, 251
 Ifosfamide, 79, 83, 345, 453, 467, 469, 526, 550
 IgG4-positive multi-organ lymphoproliferative syndrome, 271
 IL-10, 230, 287
 IL-2, 155, 229, 286, 373, 546, 555
 Imatinib mesylate, 561
 Immune response, 3, 35, 57, 139, 142, 245, 246, 247, 248, 249, 250, 253, 277, 281, 380, 398, 411, 491
 Immune system, 6, 140, 380, 491
 Immunization, 57, 251
 Immunochemotherapy, 12, 28, 188, 205, 228, 257, 317, 329, 377, 457, 472, 476
 Immunocompetent patients, 18, 40
 Immunocytoma, 421
 Immunoglobulin genes, 282, 397
 Immunohistochemical analysis, 346, 491

Immunohistochemistry, 33, 34, 35, 37, 41, 42, 70, 71, 75, 76, 87, 88, 92, 129, 131, 156, 184, 187, 189, 190, 194, 198, 231, 232, 236, 268, 281, 299, 321, 360, 392, 393, 436, 440, 456, 459, 462, 476, 482, 520, 540, 585
 Immunohistological analysis, 503
 Immunophenotyping, 35, 68, 69, 112, 142, 177, 187, 201, 269, 296, 297, 299, 362, 366, 413, 504, 515, 520, 574, 579
 Immunostaining, 51, 177, 293, 299
 Immunosuppression, 60, 140, 250
 Immunotherapy, 57, 66, 245, 250, 251, 305, 333, 342, 382, 492, 513, 556
 Indolent lymphoma, 15, 67, 72, 250, 290, 302, 334, 349, 397, 418, 422, 426, 429, 443, 502, 569, 588
 Indolent lymphoma, advanced stage, 429
 Infection, 6, 18, 41, 81, 84, 102, 115, 146, 181, 215, 220, 228, 241, 261, 265, 276, 294, 315, 346, 356, 357, 359, 406, 407, 409bis, 441, 444, 477, 484, 488, 499, 501, 516, 520, 531, 538, 554, 565, 569
 Infectious complications, 171, 182, 302, 460, 572
 Influenza, 46
 Informed consent, 19, 144
 Intention-to-treat analysis, 211
 Interferon alpha, 3, 28, 142, 246, 300, 326, 329, 336, 337, 341, 398, 409bis, 419
 Interleukin-1, 230, 286, 400
 Interleukin-10, 148, 230, 286, 381
 Interleukin-2, 96, 155, 229, 286, 373, 381, 520, 546, 555
 Interleukin-2 receptor, 97
 Interleukin-4, 286, 352
 Interleukin-6, 132, 380, 398
 International Prognostic Index, 1, 11, 30, 38, 39, 51, 52, 53, 54bis, 76, 92, 93, 94, 95, 113, 114, 126, 135, 146, 185, 186, 188, 189, 196, 197, 199, 202, 203, 205, 206, 207, 210, 210, 214, 218, 219, 226, 229, 233, 238, 239, 240, 257, 300, 304, 310, 316, 327, 328, 330, 335, 339, 341, 350, 354, 355, 363, 364, 366, 383, 389, 396, 397, 405, 434, 437, 439, 442, 445, 448, 454, 455, 456, 459, 461, 462, 465, 466, 470, 471, 472, 473, 474, 476, 480, 493, 494, 506, 507, 514, 515, 550, 569, 581, 589, 593, 594, 599

International Prognostic Index, age adjusted, 459, 578

Interphase FISH analysis, 392
 Intrathecal chemotherapy, 9, 39, 63, 81, 224, 352, 438, 486, 487, 492
 Intrathecal methotrexate, 9, 64
 Intratumoral chemotherapy, 139, 253, 287
 Intravascular lymphoma, 267
 Intravascular lymphomatosis, 267
 Involved field radiotherapy, 62, 78, 180, 181, 325
 IPI score, 76, 94, 185, 203, 238, 328, 339, 397, 445, 456, 465, 480, 550, 572

J

JC virus, 141

K

Kaposi's sarcoma, 277
 Keyhole limpet hemocyanin, 57, 248
 KIT, 132, 290

L

Large B-cell lymphoma, 351, 363, 364, 480, 484, 587
 Large T-cell lymphoma, 98
 Late toxicity, 156, 210, 453, 523, 561, 565, 563, 573
 LD-PCR, 82, 276
 Leukemia, 8, 24, 25, 26, 31, 49, 55, 59, 82, 85, 86, 112, 122, 147, 162, 165, 173, 206, 226, 244, 245, 267, 269, 281, 282, 284, 287, 291, 297, 370, 371, 373, 381, 382, 387, 392, 400, 407, 408, 409, 412, 433, 440, 504, 516, 537, 557, 576, 580

Leukemia, acute lymphoblastic, 8, 82, 83, 135, 138, 171, 178, 179, 245, 269, 330, 407, 449, 475, 579
 Leukemia, acute myeloid, 63, 162, 245, 267, 338, 436, 537, 580
 Leukemia, chronic lymphocytic, 19, 21, 22, 23, 24, 25, 26, 59, 60, 67, 101, 102, 107, 111, 112, 132, 145, 245, 254, 256, 274, 278, 281, 297, 334, 341, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382, 384, 385, 387, 398, 400, 408, 409, 410, 411, 412, 413, 414, 415, 417, 440, 555, 567, 583
 Leukemia, chronic myelogenous, 396
 Leukoencephalopathy, 66, 498
 Leukopenia, 18, 63, 307, 428, 432
 Liposomal doxorubicin, 463
 Long-term follow-up, 40, 90, 91, 124, 226, 332, 361, 429
 Long-term survival, 248, 359, 481, 484, 512
 Long-term toxicity, 52, 77, 85, 181, 464
 Lung cancer, 4, 211
 Lung cancer, non-small-cell, 264, 564
 Lung cancer, small-cell, 101, 538
 Lymph nodes, 56, 86, 115, 122, 177, 187, 200, 266, 281, 318, 382, 392, 409, 412, 433, 490, 511, 522, 535, 556, 585
 Lymphadenectomy, 411
 Lymphoblastic leukemia, 180
 Lymphoblastic lymphoma, 150, 178, 179, 230, 244, 475, 579
 Lymphoid malignancies, 19, 25, 47, 92, 101, 104, 107, 108, 482
 Lymphoma diagnosis, 585
 Lymphoma management, 122
 Lymphoma transformation, 196
 Lymphoma, aggressive, 9, 49, 53, 89, 93, 120, 192, 214, 261, 262, 268, 290, 322, 393, 397, 418, 432, 452, 460, 575, 588
 Lymphoma, Burkitt's, 8, 146, 193, 224, 275, 496
 Lymphoma, Burkitt-like, 282, 496
 Lymphoma, central nervous system, 490
 Lymphoma, childhood, 174
 Lymphomagenesis, 6, 105, 106, 195, 280, 283, 284, 291, 391, 435, 499, 595
 Lymphomatous meningitis, 486, 490
 Lymphopenia, 101, 140, 254, 255, 307
 Lymphoplasmacytic lymphoma, 341, 583
 Lymphoproliferative disorders, 409, 440, 574

M

Mabthera, 431
 Magnetic resonance imaging, 64, 172, 358, 489
 Malignant lymphoma, 192, 300, 341, 393, 496, 540, 551, 591
 MALT, 15, 61, 62, 97, 102, 123, 285, 313, 334, 341, 346, 350, 356, 357, 358, 359, 361, 368, 422, 479, 482, 490, 491, 492, 494, 585, 592, 598
 MALT lymphoma, 62, 123, 346, 350, 356, 358, 368, 479, 491, 598
 Mantle cell lymphoma, 1, 10, 12, 13, 107, 123, 139, 254, 299, 301, 302, 305, 306, 307, 308, 329, 332, 341, 345, 419, 429, 435, 436, 437, 438, 439, 441, 445, 446, 447, 472, 499, 555, 559, 583
 Marginal zone B-cell lymphoma, 67, 356, 368, 422, 456, 497
 Marginal zone lymphoma, 112, 315, 344, 422, 499, 500, 502, 583
 Melanoma, 385, 564
 Melphalan, 110, 165, 300, 340, 525, 553, 566
 Membrane protein, 459
 Mesna, 79, 467, 472
 Meta-analysis, 3, 66
 Methotrexate, 40, 79, 81, 165, 173, 243, 351, 441, 444, 484, 489, 504, 515
 MGUS, 59, 274, 542
 Microarray analysis, 10
 Microarrays, 10, 33, 37, 105, 112, 186, 191, 195, 206, 278, 280, 319, 320, 393, 407
 Microvessel density, 201

- Minimal residual disease, 54, 60, 82, 111, 304, 326, 378, 419, 461
 Mitoxantrone, 12, 16, 158, 165, 329, 333, 339, 377, 446, 537, 544
 Molecular diagnosis, 269
 Molecular remission, 326, 340, 367, 504, 529
 Monoclonal antibodies, 1, 3, 18, 85, 99, 100, 111, 130, 132, 140, 145, 194, 253, 256, 281, 325, 334, 363, 399, 403, 414, 415, 440, 459, 471, 473, 501, 529, 566, 580
 Monoclonal gammopathy, 25, 273, 275
 Mononuclear cells, 55, 200, 229, 283, 357, 398, 458, 541, 547
 MOPP regimen, 224
 Mucositis, 8, 84, 138, 212, 227, 262
 Multiple myeloma, 25, 49, 104, 132, 147, 274, 287, 295, 368, 448
 Multiple myeloma, 25, 49, 104, 110, 132, 147, 274, 287, 295, 368, 445, 539
 MUM1 expression, 458
 Myc, 195, 245, 260, 397
 Mycosis fungoides, 122, 241, 244, 261, 515
 Myeloma cells, 293, 299
 Myelosuppression, 83, 262, 429, 512, 568
 MZL, 61, 67, 99, 135, 220, 266, 281, 296, 348, 494, 501, 503, 583
- N**
- Nasopharyngeal carcinoma, 408
 Neurotoxicity, 66, 135, 181, 223, 529
 Neutropenia, 9, 15, 17, 19, 65, 102, 164, 173, 177, 206, 212, 217, 221, 227, 244, 255, 257, 261, 265, 300, 306, 307, 333, 334, 335, 377, 378, 420, 422, 423, 424, 425, 430, 441, 443, 444, 446, 448, 460, 465, 469, 470, 504, 526, 527, 531, 536, 537, 547, 549, 565, 572
 NF- κ B activation, 61, 236, 276, 281
 NK cells, 37, 142, 380, 398, 511, 546, 561
 Nodular sclerosis, 481, 518, 521, 522, 534, 538
 Non-Hodgkin's lymphoma, 2, 8, 16, 20, 27, 31, 49, 76, 83, 84, 85, 94, 98, 99, 100, 102, 119, 120, 121, 122, 126, 132, 142, 143, 144, 147, 149, 150, 154, 162, 172, 173, 175, 178, 181, 191, 199, 200, 201, 202, 203, 210, 212, 217, 219, 220, 222, 223, 225, 226, 233, 250, 251, 254, 258, 260, 263, 265, 268, 274, 285, 297, 307, 315, 316, 325, 329, 332, 342, 344, 345, 355, 358, 365, 386, 387, 388, 389, 390, 396, 397, 399, 401, 403, 419, 420, 423, 425, 427, 428, 429, 434, 436, 437, 443, 448, 453, 461, 467, 468, 469, 472, 478, 482, 490, 496, 497, 498, 499, 502, 510, 514, 515, 526, 536, 542, 544, 547, 548, 549, 551, 553, 557, 565, 566, 567, 569, 572, 576, 577, 578, 580, 581, 582, 585, 586, 592, 593, 594, 599
 Non-Hodgkin's lymphoma, aggressive, 202, 453, 552
 Non-myeloablative regimen, 112
 Nucleotide polymorphism, 75, 197
- O**
- Ocular adnexa, 41, 356, 358, 479, 490, 491, 492, 493, 497
 Oncogenes, 50, 104, 284, 291, 396
 Orchiectomy, 64
 Osteosarcoma, 564
 Outcome prediction, 72
 Outpatient, 9, 141, 303, 417, 425, 431, 452, 465, 468, 501
 Ovarian function, 161
 Oxaliplatin, 401, 468, 529
- P**
- p21, 51, 157, 308, 348, 449, 530, 562
 p27, 189, 308, 319, 449, 562
 p53, 10, 46, 51, 129, 179, 195, 196, 319, 372, 374, 403, 412, 449, 530, 562
 p53 gene, 180
 Paclitaxel, 218
 Pain, 102, 334, 361, 412, 511, 533, 534, 570
 Pancreatic cancer, 533
 PARP, 154, 260, 452
 Patient outcome, 54bis, 322
 Patients, 5, 13, 52, 119, 120, 134, 163, 171, 172, 208, 219, 235, 239, 382, 441, 453, 484, 494, 496, 513, 547, 569, 577, 582, 590, 597
 Patients, attitude to cancer, 170
 PCR analysis, 334
 PCR negativity, 334
 Pediatric patients, 77, 174
 Pediatric protocol, 8
 Pegfilgrastim, 460, 548, 552
 Pentostatin, 334, 507
 Pericardial effusion, 483
 Peripheral blood, 30, 56, 67, 111, 142, 176, 224, 229, 246, 249, 252, 256, 277, 286, 318, 324, 331, 339, 357, 369, 370, 378, 383, 398, 409, 414, 433, 437, 458, 484, 506, 509, 512, 541, 543, 545, 546, 547, 548, 549, 552, 563, 567
 Peripheral blood lymphocytes, 247
 Peripheral blood stem cells, 541, 543, 549, 566
 Peripheral blood stem cells collection, 551
 Peripheral blood stem cells transplantation, 509, 512, 546, 547, 555
 Peripheral T-cell lymphoma, 1, 35, 37, 68, 97, 113, 114, 122, 134, 172, 230, 231, 232, 233, 234, 236, 241, 412, 512, 517
 PET scanning, 52, 78, 127
 Pharmacodynamic endpoints, 207
 Pharmacokinetics, 53, 138, 141, 259
 Phase I study, 13, 17, 19, 20, 40, 51, 54, 63, 66, 85, 94, 96, 99, 102, 103, 125, 135, 136, 137, 138, 139, 141, 142, 145, 158, 206, 212, 213, 217, 220, 226, 242, 243, 244, 247, 249, 254, 256, 257, 258, 259, 261, 262, 263, 265, 293, 306, 329, 332, 344, 345, 368, 378, 399, 402, 415, 419, 420, 429, 441, 443, 445, 447, 448, 461, 465, 479, 492, 528, 531, 553, 560
 Phase I/II study, 17, 20, 139, 145, 244, 247, 256, 293, 306, 402, 419, 464
 Phase II study, 13, 40, 51, 54, 63, 66, 85, 94, 96, 102, 103, 125, 135, 137, 139, 141, 142, 158, 206, 212, 213, 217, 220, 226, 242, 243, 247, 257, 258, 259, 262, 263, 306, 329, 332, 344, 345, 368, 378, 420, 429, 441, 443, 445, 447, 448, 465, 479, 492, 528, 531, 553, 560
 Phase III study, 95
 Phase III study, 13, 51, 54, 85, 139, 206, 213, 247, 257, 330
 Plasma DNA, 596
 Platelet count, 114, 409bis, 422, 531, 576
 Platelet transfusion, 15, 303, 420, 424, 576
 PMBL, 42, 43, 50, 84, 354
 Point mutation, 410
 Polymerase chain reaction, 10, 22, 23, 41, 42, 59, 60, 64, 69, 70, 80, 82, 100, 107, 140, 155, 176, 194, 195, 196, 200, 229, 232, 260, 267, 270, 272, 275, 278, 279, 291, 324, 326, 333, 334, 347, 351, 357, 371, 372, 381, 390bis, 392, 393, 398, 406, 408, 413, 440, 458, 463, 491, 577
 Poor outcome, 24, 30, 86, 168, 199, 201, 220, 243, 434, 453, 475, 577
 Population-based, 75, 91, 150, 274, 311, 327, 355, 597
 Positron emission tomography, 4, 5, 8, 13, 15, 52, 77, 78, 116, 117, 120, 121, 122, 123, 124, 125, 126, 129, 136, 137, 138, 159, 160, 161, 164, 172, 202, 203, 204, 210, 325, 342, 358, 412, 419, 420, 422, 425, 432, 445, 447, 465, 481, 486, 526, 528, 531, 535, 578, 580, 581, 583, 584, 585, 586, 590
 Post-transplant lymphoproliferative disorder, 86
 Post-treatment evaluation, 589
 Predictive factors, 350, 575
 Prednisolone, 12, 158, 183, 201, 305, 329, 337
 Prednisone, 110, 166, 171, 173, 212, 227, 295, 335, 337, 412, 448, 460, 461, 484
 Pregnancy, 160, 564, 598
 Primary effusion lymphoma, 277
 Primary mediastinal B-cell lymphoma, 42, 50
 Primary mediastinal large B-cell lymphoma, 109
 Prognostic factors, 11, 22, 23, 27, 31, 34, 77, 82, 93, 113, 114, 116, 120, 130, 168, 175, 180, 185, 188, 189, 192, 194, 197, 199, 203, 204, 214, 216, 218, 219, 224, 229, 233, 237, 238, 240, 269, 290, 317, 326, 335, 338, 342, 350, 351, 352, 359, 360, 365, 366, 370, 371, 389, 397, 410, 411, 414, 415, 424, 454, 455, 474, 485, 496, 505, 506, 507, 509, 510, 518, 520, 522, 523, 540, 575, 584
 Prognostic index, 58, 93, 114, 232, 233, 240, 327, 350, 437, 442
 Prognostic marker, 22, 23, 51, 71, 185, 189, 194, 198, 256, 396, 408, 456, 457, 485, 545
 Prognostic model, 58, 93, 311, 517, 599
 Prognostic value, 34, 116, 130, 185, 188, 229, 317, 326, 350, 359, 360, 370, 410, 411, 454, 474, 525
 Progression-free survival, 1, 16, 39, 40, 52, 117, 130, 139, 145, 183, 210, 216, 221, 233, 240, 249, 250, 290, 307, 310, 331, 332, 337, 356, 364, 379, 411, 425, 445, 447, 457, 474, 558
 Progressive multifocal leukoencephalopathy, 141
 Proliferation, 6, 10, 26, 34, 42, 72, 87, 88, 102, 104, 106, 132, 139, 190, 197, 206, 270, 278, 282, 293, 319, 347, 360, 372, 381, 390, 397, 436, 522, 562
 Proliferation index, 319, 360, 399
 Prolonged response, 342
 ProMACE-CytaBOM, 517
 Prostate cancer, 404
 Protease inhibitors, 533
 Proteasome inhibition, 309
 Purine analogs, 111, 334, 412
- Q**
- Quality of life, 110, 309, 421, 448, 532, 533, 567, 599
 Quantitative PCR, 176, 324, 458, 596
- R**
- Radiation dose, 170, 332, 420, 591
 Radioimmunotherapy, 15, 16, 18, 19, 20, 54, 303, 325, 331, 342, 341, 344, 419, 420, 442, 465, 472, 521, 553, 576
 Radiosensitivity, 591
 Radiotherapy, 4, 5, 29, 40, 44, 53, 64, 65, 78, 90, 91, 116, 117, 120, 124, 164, 166, 167, 174, 180, 208, 214, 227, 229, 237, 238, 310, 324, 339, 342, 354, 356, 365, 388, 406, 409, 418, 438, 453, 454, 460, 480, 482, 489, 490, 492, 493, 495, 505, 506, 510, 516, 523, 524, 534, 535, 551, 553, 554, 561, 564, 568, 589
 Randomised clinical trials, 313
 RANK, 48
 Ras, 7, 542
 Rasburicase, 85
 REAL classification, 499, 513
 Real-time quantitative PCR, 83
 Recombinant idotype, 251
 Relapsed follicular lymphoma, 340, 425
 Relapsed lymphoma, 550
 Relapsed/refractory lymphoma, 17
 Remission, 1, 13, 15, 16, 28, 29, 49, 65, 66, 78, 83, 90, 98, 116, 119, 120, 122, 124, 125, 138, 141, 156, 161, 163, 166, 167, 171, 180, 192, 200, 206, 210, 212, 217, 219, 222, 226, 227, 238, 239, 243, 250, 294, 295, 300, 301, 335, 340, 341, 342, 344, 345, 359, 360, 361, 363, 367, 401, 406, 413, 416, 419, 425, 428, 429, 432, 441, 444, 454, 453, 459, 464, 465, 468, 469, 470, 472, 476, 477, 479, 481, 482, 489, 493, 494, 502, 504, 506, 512, 514, 515, 521, 533, 534, 535, 542, 544, 560, 568, 576, 577, 578, 579, 598
 Residual mass assessment, 581
 Response evaluation, 8, 18, 102, 425
 Response rates, 17, 20, 40, 210, 223, 242, 250, 257, 300, 330, 335, 344, 367, 379, 383, 385, 428, 429, 447, 456, 457, 463, 540

- Retrospective analysis, 31, 32, 58, 205, 239, 355, 432, 442, 457, 460, 466, 475, 578
- Risk factors, 52, 87, 93, 119, 125, 162, 173, 205, 206, 215, 352, 375, 438, 523, 566, 570, 579, 596
- Rituxan, 256, 485
- Rituximab, 1, 8, 9, 12, 13, 14, 15, 17, 18, 20, 28, 39, 44, 47, 53, 54bis, 58, 66, 74, 76, 83, 84, 85, 89, 98, 100, 109, 111, 132, 140, 144, 145, 171, 181, 182, 183, 186, 188, 189, 192, 198, 199, 201, 203, 207, 208, 210, 210, 212, 213, 214, 215, 216, 217, 218, 219, 220, 222, 224, 226, 228, 247, 251, 254, 257, 258, 263, 277, 279, 300, 301, 302, 303, 305, 306, 309, 310, 312, 316, 317, 323, 324, 325, 328, 329, 330, 331, 332, 334, 336, 338, 339, 344, 345, 349, 354, 355, 362, 363, 364, 367, 377, 378, 382, 398, 403, 414, 415, 419, 420, 422, 423, 425, 426, 427, 429, 430, 431, 438, 442, 444, 445, 446, 447, 448, 454, 453, 456, 457, 460, 463, 464, 465, 466, 468, 470, 471, 472, 473, 474, 480, 481, 492, 493, 494, 495, 497, 500, 501, 502, 526, 537, 541, 543, 553, 558, 566, 567, 568, 569, 573, 575, 580
- Rituximab resistance, 403, 417
- S**
- Safety profile, 103, 132, 145, 242, 369
- Salvage therapy, 29, 52, 110, 161, 169, 216, 217, 222, 336, 464, 468, 514, 528, 582
- Sarcoma, 70, 388
- Scanning electron microscopy, 400
- Sclerosis, 130
- Screening, 23, 291, 394, 408, 424
- SCT, 30, 31, 60, 140, 181, 185, 220, 233, 341, 345, 384, 475
- Second malignancies, 163
- Secondary leukemia, 160, 530
- Sequential chemotherapy, 13
- Serum levels, 53, 192, 362, 380, 483, 489
- Signal transduction pathways, 26, 72, 99, 236, 405
- Single cell, 247
- Sinuses, 266, 481
- Skin involvement, 175, 587
- Small lymphocytic lymphoma, 332, 334, 417, 439
- Solid tumors, 2, 119, 120, 132, 162, 193, 263, 267, 318, 396, 404
- Somatic mutation, 127, 370
- Spleen, 24, 47, 67, 102, 108, 172, 175, 180, 278, 303, 362, 412, 418, 433, 436, 477, 478, 500, 501, 595
- Splenectomy, 367, 500, 501, 505
- Splenic lymphoma with villous lymphocytes, 505
- Splenic marginal zone lymphoma, 266, 436, 504
- Staging, 78, 112, 120, 121, 122, 123, 159, 166, 172, 203, 310, 314, 355, 358, 410, 422, 432, 437, 438, 478, 481, 482, 498, 499, 502, 506, 512, 514, 517, 580, 581, 585, 586, 587, 589, 598
- Stanford V regimen, 170
- STAT3, 132, 155, 390, 392, 396
- Stem cells, 4, 13, 30, 33, 49, 66, 83, 110, 111, 136, 140, 141, 165, 217, 219, 221, 224, 243, 252, 262, 263, 265, 305, 307, 339, 340, 345, 362, 383, 393, 411, 437, 441, 446, 472, 475, 484, 506, 512, 526, 541, 544, 545, 547, 548, 551, 553, 559, 567
- Stem cells transplantation, 140, 252, 305, 411, 441, 472, 475, 506, 512, 551, 553, 562
- Stomach, 62, 349, 361, 388, 405, 478, 516, 583
- Suberoylanilide hydroxamic acid, 562
- Supportive care, 89, 445, 537
- Survival, 1, 2, 3, 4, 8, 10, 11, 12, 14, 16, 17, 19, 20, 22, 23, 24, 25, 27, 28, 29, 32, 38, 39, 40, 42, 44, 45, 46, 47, 51, 52, 53, 54, 54bis, 58, 60, 62, 66, 67, 71, 72, 74, 75, 76, 77, 78, 83, 85, 86, 87, 88, 89, 90, 92, 93, 96, 98, 99, 102, 104, 106, 108, 110, 111, 113, 114, 116, 117, 118, 119, 121, 122, 125, 130, 131, 132, 137, 139, 140, 146, 147, 150, 156, 162, 163, 166, 168, 178, 180, 181, 183, 185, 186, 188, 189, 190, 191, 192, 194, 196, 197, 198, 199, 201, 202, 203, 205, 207, 208, 210, 210, 210, 216, 217, 219, 220, 222, 224, 226, 228, 229, 236, 237, 238, 239, 240, 249, 250, 257, 263, 269, 274, 282, 289, 290, 300, 301, 304, 305, 310, 311, 312, 314, 316, 317, 318, 319, 321, 323, 326, 327, 328, 329, 332, 335, 337, 339, 340, 344, 345, 349, 351, 352, 354, 355, 359, 360, 364, 365, 366, 370, 371, 372, 376, 382, 383, 385, 386, 389, 390, 390bis, 392, 393, 396, 397, 405, 409bis, 411, 418, 424, 425, 426, 429, 432, 435, 437, 438, 439, 441, 442, 447, 449, 453, 454, 453, 455, 456, 457, 459, 462, 463, 464, 466, 467, 468, 470, 471, 473, 474, 475, 476, 477, 482, 484, 487, 488, 489, 493, 494, 495, 496, 497, 499, 500, 501, 503, 505, 506, 507, 508, 509, 510, 516, 517, 518, 520, 522, 523, 526, 528, 529, 533, 537, 540, 541, 542, 550, 551, 555, 563, 566, 569, 575, 576, 589, 594, 598
- Survival advantage, 2, 3, 329, 394
- Synergistic activity, 258, 445, 449
- T**
- Taxol, 218
- T-cell, 30, 31, 35, 36, 37, 87, 91, 93, 96, 103, 108, 113, 114, 122, 134, 139, 140, 150, 167, 173, 177, 179, 229, 230, 231, 232, 236, 243, 246, 249, 252, 261, 266, 286, 291, 365, 384, 436, 445, 456, 499, 508, 510, 511, 513, 558, 576, 580, 585, 595
- T-cell lymphoma, 30, 31, 35, 36, 37, 93, 96, 114, 134, 229, 230, 232, 243, 261, 266, 291, 365, 508, 511, 513, 595
- T-cell rich B-cell lymphoma, 92
- Thalidomide, 110, 132, 132, 295, 306, 445, 447, 451
- Therapeutic vaccination, 248
- Thiotepa, 67
- Thrombocytopenia, 15, 17, 18, 19, 65, 101, 136, 138, 141, 206, 217, 221, 227, 241, 244, 255, 257, 259, 264, 295, 300, 306, 307, 334, 335, 363, 378, 403, 423, 429, 441, 444, 446, 448, 465, 467, 470, 500, 503, 524, 526, 531, 547, 549, 557, 565, 576
- Topotecan, 218
- Tositumomab, 15, 132, 419, 423
- TP53 mutation, 318, 374, 377
- Transcription factors, 46, 47, 50, 69, 184, 188, 191, 197, 299, 390, 390bis, 405
- Transformed follicular lymphoma, 339, 556
- Transplantation, 14, 30, 31, 66, 119, 140, 219, 239, 240, 270, 383, 384, 446, 484, 506, 509, 512, 515, 525, 537, 540, 546, 551, 556
- Transplant-related mortality, 558
- Trastuzumab, 248
- Treatment choice, 597
- Treatment modality, 237, 344, 505, 553, 572
- Treatment outcome, 28, 129, 146, 166, 233, 301, 334, 341, 365, 424, 511
- Tumor antigen, 195, 245, 249
- Tumor burden, 123, 293, 337, 417
- Tumor diagnosis, 585
- Tumor flare, 381
- Tumor lysis syndrome, 9, 171, 262
- Tumor necrosis factor, 193
- Tumor necrosis factor- α , 192, 200, 258, 308, 314, 545
- Tumor progression, 87, 98, 132, 319, 406
- Tumor suppressor gene, 279, 284, 319, 392, 394, 408, 458, 562
- Tyrosine kinase, 24, 47, 102, 132, 561
- U**
- Unknown origin, 290, 378, 383
- V**
- Vaccination, 139, 142, 223, 246, 248, 250, 252, 254
- VACOP-B regimen, 44
- Vascular endothelial growth factor, 37, 92, 167, 199, 200, 290, 398
- VCAM-1, 37
- VEBEP regimen, 228
- V_H genes, 369, 395, 402
- Vinblastine, 81, 158, 213, 532
- Vincristine, 40, 79, 173, 183, 201, 213, 223, 305, 335, 443, 460, 464
- Vinorelbine, 515
- VP16, 13, 225
- W**
- Western blotting analysis, 438
- WHO classification, 37, 93, 123, 147, 149, 183, 272, 304, 358, 395, 457, 493, 494, 502, 514, 523
- WM, 273, 274, 314, 315, 391, 536, 540
- Z**
- Zevalin, 15, 17, 20, 303, 325, 331, 419, 421, 422, 442, 554, 565, 576